Clinical trials: CYP19
Breast Cancer
Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.
The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment
- Trial name
- CHEOPS (NCT02585388)
- Testing
- Vinorelbine, Letrozole, Anastrozole
- Where
- 47 sites in France
- Volunteers
- 120 people
- Sponsor
- ARCAGY/ GINECO GROUP
Breast Cancer
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00722072
- Testing
- fulvestrant, sorafenib tosylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Effectiveness of Zoledronic Acid in the Prevention of Osteoporosis in Early Breast Cancer Patients Receiving Letrozole
The purpose of this study is to determine whether zoledronic acid given intravenously every 6 months can prevent reduction in bone mineral density in women with early stage breast cancer receiving adjuvant therapy with the…
- Trial name
- NCT00376740
- Testing
- zoledronic acid
- Where
- 2 sites in Israel
- Volunteers
- 90 people
- Sponsor
- Soroka University Medical Center
Breast Neoplasms, mTor Protein
Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer
Tamoxifen is a classical treatment for breast metastatic cancer after 3rd generation anti-aromatase hormonotherapy in adjuvant or in metastatic line.
- Trial name
- NCT01298713
- Testing
- Tamoxifen, Everolimus
- Where
- France
- Volunteers
- 111 people
- Sponsor
- ARCAGY/ GINECO GROUP
Endometrial Cancer
Letrozole in the Treatment of Advanced or Recurrent Hormone Receptor Positive Endometrial Cancer
In Western industrialized countries, endometrial cancer is the most common malignancy of the female reproductive tract. The general therapy options are surgery, radiotherapy, chemotherapy and endocrine therapy.
- Trial name
- deFEND (NCT00171808)
- Testing
- Letrozole
- Where
- 15 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Aromatase Inhibitors
Effect of Aromatase Inhibitors on Ultrasonographic Measurements and Static and Dynamic Balance Scores in Breast Cancer
To evaluate the effects of aromatase inhibitors on lower extremity ultrasonographic measurements, static and dynamic balance scores in breast cancer patients using aromatase inhibitors
- Conditions
- Breast Cancer, Aromatase Inhibitors, Balanced
- Trial name
- NCT06184074
- Where
- Turkey (Türkiye)
- Volunteers
- 76 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Breast Cancer
High Dose Vitamin D vs Standard Dose Vitamin D Study
This study is being done to look at the difference, if there is a difference between two different doses of Vitamin D and the reduction of joint/muscle pain (arthralgia)that is caused by taking anti-estrogen medications…
- Trial name
- NCT01988090
- Testing
- 800 IU Vitamin D Supplement, 50,000 IU Vitamin D supplement
- Where
- 2 sites in United States
- Volunteers
- 93 people
- Sponsor
- Mothaffar Rimawi
Arthralgia, Breast Neoplasms
Omega-3 Supplementation in Prevention of Aromatase Inhibitor-Induced Toxicity in Patients With Stage I-III Breast Cancer
This clinical trial studies the use of omega-3 fatty acid supplementation in preventing aromatase inhibitor-induced toxicity in patients with stage I-III breast cancer.
- Trial name
- NCT02831582
- Testing
- Omega-3 Fatty Acid
- Where
- 3 sites in United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Ohio State University Comprehensive Cancer Center
Metastatic Breast Cancer
Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer
To demonstrate the efficacy of enobosarmin the treatment of androgen receptor positive (AR+) and estrogen receptor positive (ER+) metastatic breast cancer (MBC) as measured by radiographic progression free survival (rPFS).
- Trial name
- ARTEST (NCT04869943)
- Testing
- Enobosarm, Exemestane
- Where
- 54 sites in United States, Poland and 2 more
- Volunteers
- 52 people
- Sponsor
- Veru Inc.
Breast Cancer
Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor
Based on the results of the phase Ib/II study, the investigators hypothesize that combining a RET inhibitor lenvatinib with endocrine therapy letrozole improves objective response and progression-free survival compared to…
- Trial name
- NCT05181033
- Testing
- Lenvatinib + Letrozole, Fulvestrant
- Where
- Singapore
- Volunteers
- 120 people
- Sponsor
- National University Hospital, Singapore
Breast Cancer
Sj-subway, a Predictor for the Recurrence of High-risk Hormone Receptor-positive Breast That is Sensitive to Extended Endocrine Therapy
Hormone receptor-positive breast cancer accounts for about 70% of all breast cancers. Extended endocrine therapy with aromatase inhibitor is the current main treatment for hormone receptor-positive breast cancer.
- Trial name
- NCT04476485
- Testing
- endocrine therapy
- Where
- 12 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Shengjing Hospital
Inguinal Hernia Unilateral, Inguinal Hernia Bilateral
Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males
This is a prospective, single-center, two-arm Phase 1 safety and feasibility trial evaluating anti-estrogen therapy in men age 50 years and older with symptomatic unilateral inguinal hernias.
- Conditions
- Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia, Without Mention of Obstruction or Gangrene
- Trial name
- RIGHT (NCT07604272)
- Testing
- Fulvestrant, Anastrozole (ARIMIDEX™)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Vaginal Atrophy in Breast Cancer Patients
Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer
The purpose of this study is to confirm the efficacy of intravaginal prasterone (DHEA) on moderate to severe (MS) and most bothersome symptoms (MBS) of vulvovaginal atrophy (VVA) due to natural, surgical or treatment-induced…
- Trial name
- NCT03740945
- Testing
- Prasterone (DHEA)
- Sponsor
- EndoCeutics Inc.
Breast Cancer, Hormone Receptor Positive Tumor
Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer
This study is to find out if an investigational drug called Durvalumab (MEDI4736) given together with a standard of care aromatase inhibitor drug can help people with breast cancer.
- Trial name
- NCT03874325
- Testing
- Durvalumab, Anastrozole 1mg, Letrozole 2.5mg
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer, Joint Pain
Trial of Blue Citrus Compared to Placebo in Patients Receiving Aromatase Inhibitor Therapy for Estrogen Receptor Positive Post-Menopausal Breast Cancer
This purpose of this study is to determine if the herbal compound, Blue Citrus, decreases joint and bone pain associated with Aromotase Inhibitor therapy (AIT).
- Trial name
- NCT00702858
- Testing
- Blue Citrus
- Volunteers
- 30 people
- Sponsor
- Legacy Health System
Breast Cancer
Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)
This study is a primary investigation to determine the usefulness and safety of a short course of a relatively high dose of letrozole (a medication used to decrease the female hormone estrogen which is produced locally inside the…
- Trial name
- RFCLET2 (NCT01129622)
- Testing
- letrozole
- Where
- Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mount Sinai Hospital, Canada
Breast Cancer, Solid Tumors, Adult
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid…
- Trial name
- PIKALO-1 (NCT05768139)
- Testing
- STX-478, Fulvestrant, Ribociclib
- Where
- 65 sites in United States, Belgium and 7 more
- Volunteers
- 880 people
- Sponsor
- Eli Lilly and Company
Stage I Breast Cancer, Stage II Breast Cancer
Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer
This randomized phase I trial is studying the side effects of celecoxib in treating postmenopausal women with invasive breast cancer who are scheduled to undergo surgery at Memorial Sloan-Kettering Cancer Center.
- Conditions
- Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00070057
- Testing
- celecoxib, therapeutic conventional surgery, pharmacological study
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Autism Spectrum Disorder (ASD
Combination of Supplements for Treating Autistic Spectrum Disorder
A pilot study to compare the efficacy of a combination of apitherapy supplements versus placebo in children with autistic spectrum disorder.
- Trial name
- APITSA (NCT06756711)
- Testing
- A combination of apitherapy and plant extracts
- Where
- 2 sites in Romania
- Volunteers
- 40 people
- Sponsor
- Fundatia Bio-Forum
Breast Neoplasm Malignant Primary, Lymphedema Arm
Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer Survivors
As survival rates following breast cancer surgery continue to improve, long-term survivorship management has emerged as a crucial clinical priority.
- Conditions
- Breast Neoplasm Malignant Primary, Lymphedema Arm, Medication Adherence, Ductal Carcinoma In Situ
- Trial name
- Pinkmate (NCT07911839)
- Testing
- Cohort1: Pinkmate Agentic AI-ePRO Active Management Platform, Cohort1: Pinkmate Basic Medication Reminders and Standard Outpatient Care, Cohort2: InBody BWA ON Home Bioimpedance Monitoring and Behavioral App
- Where
- South Korea
- Volunteers
- 264 people
- Sponsor
- Chang-Ik Yoon